[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse STARD13

Summary
SymbolSTARD13
NameStAR-related lipid transfer (START) domain containing 13
Aliases GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ......
Chromosomal Location13q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Membrane; Peripheral membrane protein; Cytoplasmic side. Mitochondrion membrane; Peripheral membrane protein; Cytoplasmic side. Lipid droplet.
Domain PF00620 RhoGAP domain
PF07647 SAM domain (Sterile alpha motif)
PF01852 START domain
Function

GTPase-activating protein for RhoA, and perhaps for Cdc42. May be involved in regulation of cytoskeletal reorganization, cell proliferation and cell motility. Acts a tumor suppressor in hepatocellular carcinoma cells.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001667 ameboidal-type cell migration
GO:0002040 sprouting angiogenesis
GO:0002042 cell migration involved in sprouting angiogenesis
GO:0003158 endothelium development
GO:0003159 morphogenesis of an endothelium
GO:0010594 regulation of endothelial cell migration
GO:0010596 negative regulation of endothelial cell migration
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010633 negative regulation of epithelial cell migration
GO:0016525 negative regulation of angiogenesis
GO:0030336 negative regulation of cell migration
GO:0035239 tube morphogenesis
GO:0040013 negative regulation of locomotion
GO:0043534 blood vessel endothelial cell migration
GO:0043535 regulation of blood vessel endothelial cell migration
GO:0043537 negative regulation of blood vessel endothelial cell migration
GO:0043542 endothelial cell migration
GO:0045765 regulation of angiogenesis
GO:0048514 blood vessel morphogenesis
GO:0051056 regulation of small GTPase mediated signal transduction
GO:0051271 negative regulation of cellular component movement
GO:0060562 epithelial tube morphogenesis
GO:0061154 endothelial tube morphogenesis
GO:0090049 regulation of cell migration involved in sprouting angiogenesis
GO:0090051 negative regulation of cell migration involved in sprouting angiogenesis
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0097498 endothelial tube lumen extension
GO:1901342 regulation of vasculature development
GO:1901343 negative regulation of vasculature development
GO:1903670 regulation of sprouting angiogenesis
GO:1903671 negative regulation of sprouting angiogenesis
GO:2000146 negative regulation of cell motility
GO:2000181 negative regulation of blood vessel morphogenesis
Molecular Function GO:0005096 GTPase activator activity
GO:0008047 enzyme activator activity
GO:0030695 GTPase regulator activity
GO:0060589 nucleoside-triphosphatase regulator activity
Cellular Component GO:0005811 lipid particle
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-194840: Rho GTPase cycle
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
Summary
SymbolSTARD13
NameStAR-related lipid transfer (START) domain containing 13
Aliases GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ......
Chromosomal Location13q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between STARD13 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSTARD13
NameStAR-related lipid transfer (START) domain containing 13
Aliases GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ......
Chromosomal Location13q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of STARD13 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSTARD13
NameStAR-related lipid transfer (START) domain containing 13
Aliases GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ......
Chromosomal Location13q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of STARD13 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.8720.0399
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.4380.171
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4630.602
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2250.578
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5640.795
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2040.941
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0940.818
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1750.895
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3470.819
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.040.964
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7810.512
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2590.0358
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of STARD13 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.45.51.90.66
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSTARD13
NameStAR-related lipid transfer (START) domain containing 13
Aliases GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ......
Chromosomal Location13q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of STARD13. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSTARD13
NameStAR-related lipid transfer (START) domain containing 13
Aliases GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ......
Chromosomal Location13q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of STARD13. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by STARD13.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSTARD13
NameStAR-related lipid transfer (START) domain containing 13
Aliases GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ......
Chromosomal Location13q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of STARD13. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSTARD13
NameStAR-related lipid transfer (START) domain containing 13
Aliases GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ......
Chromosomal Location13q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of STARD13 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSTARD13
NameStAR-related lipid transfer (START) domain containing 13
Aliases GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ......
Chromosomal Location13q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between STARD13 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSTARD13
NameStAR-related lipid transfer (START) domain containing 13
Aliases GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ......
Chromosomal Location13q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting STARD13 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.